Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-30

FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Zepzelca (lurbinectedin) by Jazz Pharmaceuticals, Inc. The action approves changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zepzelca (lurbinectedin)

Snippet

SUPPL AP for ZEPZELCA (LURBINECTEDIN)